Propanc Biopharma Inc
OTC:PPCB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Immsi SpA
SWB:IMY
|
IT |
Propanc Biopharma Inc
Total Liabilities
Propanc Biopharma Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Propanc Biopharma Inc
OTC:PPCB
|
Total Liabilities
$3.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities
$207.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities
$19.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Liabilities
AU$1.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities
AU$748.6m
|
CAGR 3-Years
62%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities
AU$11.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
27%
|
CAGR 10-Years
30%
|
|
Propanc Biopharma Inc
Glance View
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate PRP is a pharmaceutical composition consisting of two pancreatic proenzymes trypsinogen and chymotrypsinogen for treating cancer. PRP is an approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that targets and eradicates cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. PRP is a therapy based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas and could represent the body’s primary defense against cancer.
See Also
What is Propanc Biopharma Inc's Total Liabilities?
Total Liabilities
3.9m
USD
Based on the financial report for Jun 30, 2024, Propanc Biopharma Inc's Total Liabilities amounts to 3.9m USD.
What is Propanc Biopharma Inc's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
8%
Over the last year, the Total Liabilities growth was 21%. The average annual Total Liabilities growth rates for Propanc Biopharma Inc have been 8% over the past three years .
